BRIEF COMMUNICATION

Human Gut Microbiome and Risk for Colorectal Cancer

Jiyoung Ahn, Rashmi Sinha, Zhiheng Pei, Christine Dominianni, Jing Wu, Jianxin Shi, James J. Goedert, Richard B. Hayes, Liying Yang

Manuscript received April 24, 2013; revised August 16, 2013; accepted August 19, 2013.

Correspondence to: Jiyoung Ahn, PhD, Division of Epidemiology, Department of Population Health, New York University School of Medicine, 650 First Ave, New York, NY 10016 (e-mail: jiyoung.ahn@nyumc.org) and Liying Yang, MD, Division of Translational Medicine, Department of Medicine, New York University School of Medicine, 423 E 23rd St, Rm 6030W, New York, NY 10010 (e-mail: liying.yang@nyumc.org).

We tested the hypothesis that an altered community of gut microbes is associated with risk of colorectal cancer (CRC) in a study of 47 CRC case subjects and 94 control subjects. 16S rRNA genes in fecal bacterial DNA were amplified by universal primers, sequenced by 454 FLX technology, and aligned for taxonomic classification to microbial genomes using the QIIME pipeline. Taxonomic differences were confirmed with quantitative polymerase chain reaction and adjusted for false discovery rate. All statistical tests were two-sided. From 794 217 16S rRNA gene sequences, we found that CRC case subjects had decreased overall microbial community diversity (P = .02). In taxonomy-based analyses, lower relative abundance of Clostridia (68.6% vs 77.8%) and increased carriage of *Fusobacterium* (multivariable odds ratio [OR] = 4.11; 95% confidence interval [CI] = 1.62 to 10.47) and *Porphyromonas* (OR = 5.17; 95% CI = 1.75 to 15.25) were found in case subjects compared with control subjects. Because of the potentially modifiable nature of the gut bacteria, our findings may have implications for CRC prevention.

The human gut hosts a diverse community of bacteria that play key roles in modulating host metabolism and immunity (1) and in the digestion and conversion of dietary constituents into active forms (2). Although a role for this gut microbiota in colorectal cancer (CRC) in humans is suspected (3–6), particularly from comparisons of CRC tumor and adjacent normal tissue (7,8), systematic epidemiologic comparisons between CRC patients and control subjects, considering comprehensive confounders and multiple comparisons, are lacking. From stool samples, we comprehensively surveyed the distal gut microbiota by 16S rRNA gene sequencing and compared the fecal microbial profiles between CRC case subjects and matched control subjects.

We used specimens and data from a case–control study that tested whether fecal mutagens were associated with CRC (9,10). Briefly, case subjects with newly diagnosed, histologically confirmed adenocarcinoma of the colon or rectum were recruited before initiation of treatment during the period from 1985 to 1989 at three Washington, DC, area hospitals. Control subjects were recruited from contemporaneous patients awaiting elective surgery for nononcologic, nongastrointestinal conditions at these hospitals. Before hospitalization and treatment, participants completed written informed consent and diet and demographic questionnaires and provided 2-day fecal samples that were freeze-dried. The lyophilates were pooled, mixed, and stored at –40°C. Among 69 case subjects and 114 control subject, we included for study 47 colorectal cancer case subjects and 94 control subjects for whom at least 100 mg of lyophilized feces was available. Case and control subjects were frequency matched by sex and body mass index (Supplementary Table 1, available

online). One subject in the CRC case subject group used antibiotics within the past year; results remained unchanged after exclusion of this subject. This study was approved by the National Cancer Institute and the New York Univeristy Institutional Review Board.

We extracted DNA from fecal samples using the Mobio PowerSoil DNA Isolation Kit (Carlsbad, CA) with bead-beating. As we reported previously (11),16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5′GG AGGCAGCAGTRRGGAAT′-3′ and 803R 5′-CTACCRGGGTATCTAATCC-3′) incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence (12). Amplicons were sequenced with the 454 Roche FLX Titanium pyrosequencing system following the manufacturer's specifications. Laboratory personnel were blinded to case–control status.

Multiplexed, barcoded sequencing data were deconvoluted. Poor-quality sequences were filtered based on sequence less than 200 or more than 600 base pairs, missing or mean quality score less than 25, or mismatched barcode and primer sequences. Chimeric sequences were removed with ChimeraSlayer (13). Filtered sequences were binned into operational taxonomic units with 97% identity and aligned to fully-sequenced microbial genomes (IMG/GG GreenGenes) using the QIIME pipeline (14). Blinded quality control specimens in all sequencing batches (38 aliquots from 9 unmatched parent study control subjects) had good reproducibility. Intraclass correlation coefficients were 0.84 for Shannon diversity index, and 0.43 to 0.59 for relative abundances of major phyla (Supplementary Table 2, available online). To confirm sequencing associations, we performed quantitative polymerase chain reaction for genera *Fusobacterium* and *Porphyromonas* with the SYBR Green method (15) using genus-specific primer sets (16,17).

Rarefaction curves were estimated by bootstrapping of 500 random samples at 500 sequence increments. Alpha diversity (Shannon's diversity and evenness indices) differences between case and control

Figure 1. Human gut microbiome in relation to colorectal cancer case-control status. **A**) Shannon diversity index in 47 colorectal cancer case subjects and 94 control subjects. **B)** Evenness index in 47 colorectal cancer case subjects and 94 control subjects. Rarefaction curves were estimated by bootstrapping of 500 random samples at 500 sequence increments. Alpha diversity (Shannon's diversity and evenness indices) differences between case and control subjects were compared with *t* tests with Monte Carlo permutations using *compare_alpha_diversity.py*, a built-in function in the QIIME pipeline. **C**) Cladogram representation of gut microbiome taxa associated with colorectal cancer. **Red** indicates taxa enriched in colorectal cancer case subjects, and **blue** indicates taxa enriched in control subjects. Only taxa with nominal *P* less than .05 based on χ^2 test (dichotomized) or Wilcoxon test (continuous) are labeled. The tests were two-sided. Figure was constructed using data presented in in Table 1.

subjects were compared with *t* tests with Monte Carlo permutations using *compare_alpha_diversity.py*, a built-in function in the QIIME pipeline (14). Carriage (presence or absence; ie, prevalence) of specific taxa was compared by χ^2 analysis, and relative abundances were compared using the nonparametric Wilcoxon test. Odds ratios (ORs) were calculated for taxa, based on logistic regression,

adjusting for age and, additionally, for sex, body mass index, race, smoking, and sequencing batch. We report nominal *P* values and highlight associations that meet a false discovery rate (FDR) adjusted *P* less than or equal to .05 by the Benjamini and Hochberg method (18). All statistical tests were two-sided, and a *P* value of less than .05 was considered statistically significant.

From the 141 fecal study samples (n = 47 CRC case subjects and 94 control subjects), we obtained 794 217 16S rRNA filtered gene sequences (mean ± standard deviation = 4919 ± 2942 reads per sample in control subjects and 4863 ± 2784 per sample in case subjects; *P* = .91). We assessed sample gut microbial community structure by diversity (ie, how many different taxa are present) and evenness (ie, how

Table 1. Prevalence and relative abundance of selected fecal microbial taxa in 47 colorectal cancer case subjects and 94 control subjects

Taxa (Phylum; class; order; family; genus)	% positive (carriage)*			Age-adjusted OR (95% CI)	Multivariable OR (95% CI)#	Abundance %†		
	Case	Control	P‡			Case	Control	P§
Firmicutes;Clostridia (class)	100.0	100.0	NA	NA	NA	68.6	77.8	.005||
Firmicutes;Clostridia;Clostridiales (order)	100.0	100.0	NA	NA	NA	68.5	77.6	.006
Firmicutes;Clostridia;Clostridiales; Lachnospiraceae;Ruminococcus	89.4	97.9	.02	0.18 (0.032 to 0.95)	0.14 (0.024 to 0.85)	1.5	1.5	.49
Firmicutes;Clostridia;Clostridiales; Lachnospiraceae;Coprococcus	93.6	97.9	.20	0.34 (0.054 to 2.14)	0.33 (0.055 to 2.42)	1.7	3.7	.002||
Firmicutes;Clostridia;Clostridiales; Lachnospiraceae;Other	100.0	98.9	.48	NA	NA	16.1	21.2	.005||
Firmicutes;Clostridia;Clostridiales; Clostridiaceae (family)	4.3	0.0	.04	NA	NA	0.04	0.0	NA
Firmicutes; Clostridia;Clostridiales; ClostridialesFamilyXIII. IncertaeSedis;Anaerovorax	4.3	0.0	.04	NA	NA	0.3	0.0	NA
Firmicutes;Clostridia;Clostridiales; ClostridialesFamilyXIII. IncertaeSedis;Other	44.7	26.6	.03	2.31 (1.10 to 4.86)	2.38 (1.12 to 5.06)	0.06	0.1	.49
Firmicutes;Clostridia;Clostridiales; Peptostreptococcaceae; Peptostreptococcus	10.6	2.1	.03	5.26 (0.97 to 28.46)	4.98 (0.87 to 28.53)	0.03	0.0	.33
Firmicutes;Clostridia;Clostridiales; Veillonellaceae (family)	25.5	10.6	.02	2.79 (1.10 to 7.09)	3.02 (1.16 to 786)	0.08	0.2	.37
Firmicutes;Clostridia;Clostridiales; Veillonellaceae;Megasphaera	14.9	4.3	.03	4.14 (1.13 to 15.19)	4.02 (1.03 to 15.70)	0.4	0.3	.78
Firmicutes;Clostridia;Clostridiales; Veillonellaceae;Selenomonas	4.3	0.0	.04	NA	NA	0.06	0.0	NA
Fusobacteria (phylum)	36.2	16.0	.007||¶	3.71(1.85 to 7.46)	4.37 (2.10 to 9.09)	0.06	0.1	.13
Fusobacteria;Fusobacteria;Fusobacteriales; Fusobacteriaceae;Fusobacterium	31.9	11.7	.004||¶	3.74 (1.53 to 9.12)	4.11 (1.62 to 10.47)	0.07	0.1	.32
Actinobacteria;Actinobacteria; Coriobacteriales (family)	46.8	69.2	.01	0.41 (0.20 to 0.86)	0.42 (0.20 to 0.90)	0.2	0.2	.99
Actinobacteria;Actinobacteria;Coriobacteriales;Coriobacteriaceae; Atopobium	19.2	2.1	<.001||¶	11.15 (2.28 to 54.50)	14.36 (2.78 to 74.30)	0.1	0.2	.13
Bacteroidetes;Bacteroidia;Bacteroidales; Porphyromonadaceae;Porphyromonas	27.7	7.5	.001 ||¶	4.58 (1.66 to 12.60)	5.17 (1.75 to 15.25)	0.1	0.2	.58

*   Percentage of case and control subjects who carry the specific taxon. NA = not assessed.

†   Median relative abundance of the specific taxon in people who carry the taxon. NA = not assessed.

‡ P values were based on χ^2 test (two-sided).

§ P values were based on nonparametric Wilcoxon test (two-sided).

\|\| False discovery rate–adjusted P values were P less than or equal to .05.

¶   False discover rate tested limited to taxa with at least 0.05% relative abundance for Wilcoxon test (62 tests for genera).

Multivariable odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for taxa, based on logistic regression with noncarriers as the referent, adjusting for age, sex, body mass index, race, smoking, and sequencing batch.

evenly distributed are the taxa in a sample) and found that CRC case subjects had decreased community diversity (*P* = .02) (Figure 1A) but did not differ from control subjects on community evenness (*P* = .43) (Figure 1B).

We compared case and control subjects for presence and relative abundance of taxa. Case subjects tended to have enrichment of phylum Bacteroidetes (16.2% vs 9.9% relative abundance for case and control subjects, respectively) and depletion of Firmicutes (74.0% vs 80.3% for case and control subjects, respectively) (Supplementary Figure 1, available online). Within Firmicutes, the relative depletion was most prominent for the class Clostridia (68.6% vs 77.8%; *P* = .005; FDR-adjusted *P* ≤ .05), including *Coprococcus* and other taxa in the family *Lachnospiraceae* (Table 1; Figure 1C). Gram-positive Clostridia, especially *Coprococcus*, efficiently ferment dietary fiber and other complex carbohydrates to butyrate, a major colonic metabolite that may inhibit colonic inflammation and carcinogenesis (2,19). Consistent with our result, Clostridia have also been reported to be less abundant in colon tumors than in adjacent normal tissue (7).

Carriage of the genus *Fusobacterium* was statistically significantly greater in case subjects (31.9% vs 11.7% in control subjects) (Table 1; Figures 1C) and was associated with increased CRC risk (multivariable-adjusted OR = 4.11; 95% confidence interval [CI] = 1.62 to 10.47; *P* = .004; FDR-adjusted *P* ≤ .05). Relative abundance of *Fusobacterium* taxa in carriers did not differ (case subject range = 0.009%–28.9%; control subject range = 0.01%–1.3%; *P* = .32) (Table 1).

Gram-negative, anaerobic *Fusobacterium* contributes to colitis (20) and to periodontal disease (21), which itself may be related to colon cancer (22). Consistent with our findings, two studies recently reported that *Fusobacterium* was enriched in human CRC tissue compared with adjacent normal tissue (7,8), and another study reported enrichment of *Fusobacterium* in rectal swabs from CRC case subjects compared with control subjects (23).

In our study, increased carriage of genera *Atopobium* and *Porphyromonas* was also associated with CRC (OR = 14.36, 95% CI = 2.78 to 74.30, *P* < .001; and OR = 5.17, 95% CI = 1.75 to 15.25, *P* = .001, respectively)

(Table 1). *Atopobium*, a Gram-positive anaerobic bacterium, is associated with Crohn's disease (24) and reported to inhibit colon cancer apoptosis in vitro (25). *Porphyromonas*, commonly found in the mouth and gastrointestinal track, is associated with oral periodontal disease (26). Increased risks of CRC with carriage of *Porphyromonas* (*P* = .05; OR = 1.44; 32.1% vs 16.2% in case subjects vs control subjects, respectively) and of *Fusobacterium* (*P* = .01; OR = 1.44; 34.3% vs 28.1% in case subjects vs control subjects, respectively) were confirmed by quantitative polymerase chain reaction.

This is the first epidemiologic study comparing the gut microbiome of CRC patients and noncancer control subjects while controlling for potential confounders and taking into account the multiple comparisons involved in microbiome analysis. Other strengths of this study include nonculture-dependent sequencing-based microbiome assessment, which provided a comprehensive survey of the human fecal microbiome.

We did not examine mucosal adherent gut bacteria, which is a limitation because these might be more closely linked to colon carcinogenesis than are bacteria in feces. Possible effects of lyophylization and long-term frozen storage are unknown. However, lyophilization is an excellent method to preserve DNA for long-term storage (27); reproducibility in our masked replicates was good; and taxon distributions of our data are comparable with those of other published fecal microbiome data (28,29). Results from these analyses could be affected by selection bias and other biases that are common to case–control studies. Large prospective studies are warranted to confirm our findings.

In conclusion, this survey of the gut microbiota found that CRC risk was associated with decreased bacterial diversity in feces; depletion of Gram-positive, fiber-fermenting Clostridia; and increased presence of Gram-negative, proinflammatory genera *Fusobacterium* and *Porphyromonas*. Because of the potentially modifiable nature of the gut bacteria, our findings may have implications for CRC prevention.

References

1. O'Keefe SJ. Nutrition and colonic health: the critical role of the microbiota. *Curr Opin Gastroenterol*. 2008;24(1):51–58.
2. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. *Nat Rev Microbiol*. 2012;10(5):323–335.
3. Yang L, Pei Z. Bacteria, inflammation, and colon cancer. *World J Gastroenterol*. 2006;12(42):6741–6746.
4. Kinross JM, von Roon AC, Holmes E, Darzi A, Nicholson JK. The human gut microbiome: implications for future health care. *Curr Gastroenterol Rep*. 2008;10(4):396–403.
5. Horie H, Kanazawa K, Okada M, Narushima S, Itoh K, Terada A. Effects of intestinal bacteria on the development of colonic neoplasm: an experimental study. *Eur J Cancer Prev*. 1999;8(3):237–245.
6. Moore WE, Moore LH. Intestinal floras of populations that have a high risk of colon cancer. *Appl Environ Microbiol*. 1995;61(9):3202–3207.
7. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. *Genome Res*. 2012;22(2):292–298.
8. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. *Genome Res*. 2012;22(2):299–306.
9. Schiffman MH, Van Tassell RL, Robinson A, et al. Case–control study of colorectal cancer and fecapentaene excretion. *Cancer Res*. 1989;49(5):1322–1326.
10. Schiffman MH, Andrews AW, Van Tassell RL, et al. Case–control study of colorectal cancer and fecal mutagenicity. *Cancer Res*. 1989;49(12):3420–3424.
11. Ahn J, Yang Y, Paster BJ, et al. Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison. *PLoS One*. 2011;6(7):e22788–22795.
12. Nossa CW, Oberdor WE, Yang L, et al. In silico design of 16S rRNA gene primers for analysis of human foregut microbiome using next generation sequencing technology. *World J Gastroenterol*. 2010;16(33): 4135–4144.
13. Haas BJ, Gevers D, Earl AM, et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. *Genome Res*. 2011;21(3):494–504.
14. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*. 2010;7(5):335–336.
15. Sanapareddy N, Legge RM, Jovov B, et al. Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. *Isme J*. 2012;6(10):1858–1868.
16. Knoch B, Nones K, Barnett MP, McNabb WC, Roy NC. Diversity of caecal bacteria is altered in interleukin-10 gene-deficient mice before and after colitis onset and when fed polyunsaturated fatty acids. *Microbiology*. 2010;156(Pt 11):3306–3316.
17. Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria

in faecal samples by real-time PCR. *J Appl Microbiol*. 2004;97(6):1166–1177.

18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc B*. 1995;57(1):289–300.

19. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. *Aliment Pharmacol Ther*. 2008;27(2):104–119.

20. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. *Gut*. Jan 2003;52(1):79–83.

21. Signat B, Roques C, Poulet P, Duffaut D. Fusobacterium nucleatum in periodontal health and disease. *Curr Issues Mol Biol*. 2011;13(2):25–36.

22. Ahn J, Segars S, Hayes RB. Periodontal Disease, Porphyromonas gingivalis (*P. gingivalis*) serum antibody levels and orodigestive cancer mortality. *Carcinogenesis*. 2012;33(5):1055–1058.

23. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. *PLoS One*. 2012;7(6):e39743.

24. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut*. 2006;55(2):205–211.

25. Altonsy MO, Andrews SC, Tuohy KM. Differential induction of apoptosis in human colonic carcinoma cells (Caco-2) by Atopobium, and commensal, probiotic and enteropathogenic bacteria: mediation by the mitochondrial pathway. *Int J Food Microbiol*. 2010;137(2–3):190–203.

26. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet*. 2005;366(9499): 1809–1820.

27. Frantzen MA, Silk JB, Ferguson JW, Wayne RK, Kohn MH. Empirical evaluation of preservation methods for faecal DNA. *Mol Ecol*. 1998;7(10):1423–1428.

28. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. *Nature*. 2009;457(7228):480–484.

29. Human Microbiome Project: Structure, function and diversity of the healthy human microbiome. *Nature*. 2012;486(7402):207–214.

Affiliations of authors: Division of Epidemiology, Department of Population Health (JA, CD, JW, RBH), Department of Pathology (ZP), and Department of Medicine (ZP, LY), New York University School of Medicine, New York, NY; New York University Cancer Institute, New York, NY (JA, ZP, CD, JW, RBH); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (RS, JS, JJG); Department of Pathology and Laboratory Medicine, New York Veterans Affairs Medical Center, New York, NY (ZP).